3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Acute
2
Colorectal Neoplasms
2
Recurrence
1
Polycystic Ovary Syndrome
1
Obesity
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Intraocular Lymphoma
1
Inflammation
1
Hodgkin Disease
1
Frailty
1
Corneal Endothelial Cell Loss
1
Cataract
1
Breast Neoplasms
1
Anemia
1
Interventions
Cyclophosphamide
23
venetoclax
17
Dexamethasone
16
pembrolizumab
15
fludarabine
15
Cytarabine
13
pomalidomide
8
Rituximab
8
Gemcitabine
8
Carboplatin
8
Azacitidine
8
glofitamab
7
fludarabine phosphate
7
Lenalidomide
7
selinexor
6
Paclitaxel
6
Injections
6
Immunotherapy, Adoptive
6
Granulocyte Colony-Stimulating Factor
6
Cisplatin
6
daratumumab
5
Temozolomide
5
Bevacizumab
5
zanubrutinib
4
ruxolitinib
4
Surgical Procedures, Operative
4
Oxaliplatin
4
Nivolumab
4
Drug Therapy
4
Decitabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Recurrence
×
Ascorbic Acid
×
Clear all
NCT04150042
2026-01-29
SHARON
General Oncology, Inc.
Phase 1
Recruiting
24 enrolled